CEO's Beneficial Ownership Increases to 20.7% Following Significant Performance-Based Stock Grant
Summary
Fortress Biotech's CEO, Lindsay A. Rosenwald, M.D., received a significant performance-based stock grant, increasing his beneficial ownership to 20.7% of the company's common stock.
Key Events
-
CEO Receives Significant Stock Grant
Lindsay A. Rosenwald, M.D., Chairman, President, and CEO, was granted 475,424 shares of restricted common stock on March 18, 2026, under the company's Long Term Incentive Plan.
-
Grant Tied to Performance Goals
The stock grant was awarded upon the determination that the CEO achieved 100% of the relevant goals and objectives established by the Compensation Committee.
-
Beneficial Ownership Increases to 20.7%
Following this grant, the CEO's total beneficial ownership in Fortress Biotech, including currently exercisable warrants and other holdings, now aggregates 6,917,715 shares, representing approximately 20.7% of the outstanding common stock.
Analysis
This Schedule 13D/A filing reveals a substantial increase in beneficial ownership for Lindsay A. Rosenwald, M.D., the Chairman, President, and CEO of Fortress Biotech. The grant of 475,424 shares of restricted common stock, valued at over $1.4 million, is tied to the achievement of 100% of performance goals set by the Compensation Committee. This event significantly enhances insider alignment and signals confidence in the company's leadership and strategic direction, as the CEO's total beneficial ownership now stands at 20.7%.
At the time of this filing, FBIO was trading at $2.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $92.8M. The 52-week trading range was $1.33 to $4.53. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.